论文部分内容阅读
近两年来,有关马兜铃科中药(以下简称“马”药)广防己、关木通引起肾中毒和致癌的报道愈演愈烈,并迅速扩散到全世界,引起了广泛的关注。信息和影响所及,未经任何人士或部门敦促,中医处方中这类药物就自动回避,已订购的饮片和产品能退则退。这种情况与1996年日本小柴胡汤事件不同的是没有听到一点反驳或辩论的声音,似乎这“马”是洪水猛兽已成定论。作者以为不然,故作此文以争鸣。所有报道和禁用依据源于1999年7月的英国事件和90年代初的比利时事件(见本期第201页—编者注)。于是一些国家便敦促医师在开处方时除去以上成分。今年夏季,美国食品与药品管理局(FDA)在“至今未收到类似不利事件报告”的情况下,也停止进口、制造和销售已知含有和“怀疑含有马兜铃酸的原
In the past two years, reports on the cause of kidney poisoning and cancer caused by Aristolochiae and Guanmutong caused by Aristolochiaceae Chinese medicine (hereinafter referred to as “Ma”) have intensified, and have rapidly spread to the whole world, causing widespread concern. With the information and impact, without any person or department urging, such drugs in Chinese medicine prescriptions are automatically evaded, and the ordered pieces and products can be withdrawn. This situation differs from that of the 1996 Xiao Chai Hu Tang incident in Japan in that there was no sound of refutation or debate. It seems that this “horse” is a conclusive truth. The author thinks otherwise, so this article contends. All reports and bans were based on the British incident in July 1999 and the Belgian incident in the early 1990s (see page 201 - Editorial Note for this issue). So some countries urge doctors to remove the above ingredients when they write a prescription. This summer, the U.S. Food and Drug Administration (FDA) also stopped importing, manufacturing, and selling known products that contained or “are suspected to contain aristolochic acid” even though they had not received reports of similar adverse events to date.